Abiraterone acetate

Overview

Abirateroneacetate is a potent, oral Targeted Therapy used extensively in the treatment of advanced prostate cancer. As a prodrug, it is converted in the body to its active form, abiraterone, which acts as a specific inhibitor of androgen biosynthesis. It is almost always prescribed in combination with a corticosteroid (prednisone or methylprednisolone) to manage potential side effects related to mineralocorticoid excess.

• Generic Name: Abiraterone Acetate
• US Brand Names: Zytiga®, Yonsa®
• Drug Class: Androgen Biosynthesis Inhibitor (CYP17 Inhibitor)
• Route of Administration: Oral (Tablets)
• FDA Approval Status: Approved (First approved in 2011)

What Is It and How Does It Work? (Mechanism of Action)

Abiraterone acetate is a selective and irreversible inhibitor of the enzyme 17 -hydroxylase/C17,20-lyase (CYP17). This enzyme is crucial for the production of androgens (male hormones like testosterone) in the body.

Molecular Mechanism:

1. Androgen Dependence: Prostate cancer cells rely on androgens to grow and survive. Standard androgen deprivation therapy (ADT) stops the testicles from making testosterone, but it does not affect androgen production in other parts of the body.
2. CYP17 Inhibition: The CYP17 enzyme is expressed in three key locations: testicular tissue, adrenal glands, and prostate tumor tissue itself. Abiraterone inhibits the enzymatic activity of CYP17 in all three sites.
3. Biosynthesis Blockade: Specifically, it inhibits the conversion of pregnenolone and progesterone into their 17-hydroxy derivatives and subsequently into dehydroepiandrosterone (DHEA) and androstenedione. These are the precursors to testosterone.
4. Tumor Starvation: By blocking androgen production at all sources (including the tumor itself), abiraterone reduces serum testosterone to undetectable levels, effectively starving the cancer cells of the fuel they need to proliferate.

FDA-Approved Clinical Indications

Abiraterone acetate is approved for the treatment of prostate cancer in adult men. It is typically used in combination with prednisone or methylprednisolone.

Oncological Uses:

• Metastatic Castration-Resistant Prostate Cancer (mCRPC): Treatment of patients with metastatic castration-resistant prostate cancer (cancer that has spread and no longer responds to medical or surgical castration).
• Metastatic High-Risk Castration-Sensitive Prostate Cancer (mCSPC): Treatment of patients with metastatic high-risk castration-sensitive prostate cancer (cancer that still responds to testosterone suppression but is aggressive and widespread).

Non-Oncological Uses:

• There are currently no FDA-approved non-oncological indications for abiraterone acetate.

Dosage and Administration Protocols

Dosing depends on the specific formulation (Zytiga® vs. Yonsa®) as they have different bioavailability. They are NOT interchangeable.

Zytiga® (Standard Formulation)

Yonsa® (Micronized Formulation)

Dose Adjustments:

• Hepatic Impairment:
  • Mild (Child-Pugh A): No adjustment needed.
  • Moderate (Child-Pugh B): Reduce dose (e.g., Zytiga to 250 mg once daily). Monitor closely.
  • Severe (Child-Pugh C): Avoid use.
• Hepatotoxicity During Treatment: If ALT/AST rises >5x ULN or Bilirubin >3x ULN, hold treatment until recovery. Restart at reduced dose (e.g., 750 mg, then 500 mg). If recurrence occurs at 500 mg, discontinue permanently.

Clinical Efficacy and Research Results

Abiraterone has set a high standard for survival outcomes in advanced prostate cancer. Recent long-term data (2020-2025 analysis window) confirms its durable efficacy.

• mCSPC (LATITUDE Trial & STAMPEDE):
  • In high-risk metastatic castration-sensitive prostate cancer, adding abiraterone to ADT significantly improves Overall Survival (OS).
  • Updated analyses show a median OS of approximately 53 months with abiraterone + ADT versus 36.5 months with ADT alone.
  • It reduces the risk of death by approximately 34-38% in this setting.
• mCRPC (COU-AA-301 & 302 Trials):
  • In the post-chemotherapy setting (COU-AA-301), abiraterone increased median survival to 15.8 months vs. 11.2 months for placebo.
  • In the chemotherapy-naïve setting (COU-AA-302), it extended median survival to 34.7 months vs. 30.3 months, and significantly delayed the need for chemotherapy and opiates for cancer pain.
• Current Research Trends (2024): Ongoing studies are evaluating the triplet therapy efficacy (Abiraterone + ADT + Chemotherapy) and its combination with PARP inhibitors (like olaparib) for patients with DNA repair gene mutations (e.g., BRCA1/2), showing promising improvements in progression-free survival (PROpel trial data).

Safety Profile and Side Effects

BLACK BOX WARNING: NONE

While there is no Black Box Warning, abiraterone has serious warnings regarding mineralocorticoid excess and hepatotoxicity.

Common Side Effects (>10%)

• Mineralocorticoid Excess: Hypertension (high blood pressure), Hypokalemia (low potassium), Fluid Retention (edema/swelling). This occurs because CYP17 inhibition shifts steroid production toward aldosterone.
• Constitutional: Fatigue, hot flashes.
• Gastrointestinal: Diarrhea, nausea, vomiting.
• Musculoskeletal: Joint swelling or pain (arthralgia).
• Metabolic: Hypertriglyceridemia, hyperglycemia.

Serious Adverse Events

• Hepatotoxicity: Severe elevations in liver enzymes (ALT/AST) can occur, sometimes leading to acute liver failure.
• Cardiac Disorders: Atrial fibrillation, tachycardia, and heart failure (exacerbated by fluid retention).
• Adrenocortical Insufficiency: Because abiraterone blocks cortisol production, patients may require stress-dose steroids during infection or surgery.
• Hypokalemia: Severe low potassium can lead to arrhythmias.

Management Strategies:

• For Mineralocorticoid Excess: Mandatory co-administration of Prednisone (or methylprednisolone) replaces the blocked cortisol and prevents the compensatory rise in ACTH and aldosterone.
• Monitoring: Blood pressure, potassium, and fluid status must be monitored monthly.
• Hepatotoxicity: Liver Function Tests (LFTs) must be checked every 2 weeks for the first 3 months, then monthly.

Research Areas: Combination Strategies

While abiraterone is not a stem cell therapy, it is being investigated in Precision Medicine combinations.

• PARP Inhibitor Combinations: In 2023, the FDA approved the combination of Abiraterone + Olaparib (a PARP inhibitor) for BRCA-mutated metastatic castration-resistant prostate cancer. This combination targets the cancer’s inability to repair DNA damage while simultaneously starving it of hormones.
• Radioligand Therapy: Trials are ongoing to determine the optimal sequencing of abiraterone with Lutetium-177 PSMA therapy, a targeted radiopharmaceutical, to maximize tumor clearance in late-stage disease.

Patient Management and Practical Recommendations

Pre-Treatment Tests

• Liver Function Tests (LFTs): Baseline AST, ALT, and Bilirubin.
• Electrolytes: Baseline Potassium is critical.
• Cardiac Assessment: Blood pressure and history of heart failure/arrhythmia.
• Hormonal Profile: Testosterone and PSA levels.

Precautions During Treatment

• Food Effect (Zytiga): Taking Zytiga with food increases absorption by up to 10-fold, leading to dangerous toxicity. Strict adherence to the empty stomach rule is mandatory.
• Liver Monitoring: Patients must attend bi-weekly lab appointments initially.
• Steroid Adherence: Patients must not stop taking prednisone abruptly, as this can lead to adrenal crisis or severe hypertension.

Do’s and Don’ts List

• DO take your medication at the same time every day.
• DO report symptoms of liver problems (yellowing skin/eyes, dark urine) immediately.
• DO monitor your blood pressure at home if possible.
• DON’T eat for 2 hours before and 1 hour after taking Zytiga.
• DON’T stop taking prednisone without your doctor’s instruction; it is a safety partner to the drug.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and is intended for international patients and healthcare professionals. It does not constitute medical advice, diagnosis, or treatment. Abiraterone Acetate (Zytiga®, Yonsa®) is a prescription medication; its use must be determined by a qualified oncologist or urologist based on individual patient history, cardiac status, and liver function. Dosing, protocols, and approval status may vary by country and regulatory jurisdiction. Always consult with a healthcare provider regarding specific medical conditions and treatment options.